1-8 of 8
Francis J. Giles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P021: Genomic biomarkers for response to 9-ING-41, a small molecule selective glycogen synthase kinase-3 (GSK-3) inhibitor, in pancreas cancer: Preliminary results

Brittany A. Borden, Andre De Souza, Devalingam Mahalingam, Steven Powell, Pamela N. Munster, Kelsey Huntington, Andrew Mazar, Ludmila Calvacante, Francis J. Giles, Wafik S. El-Deiry, Howard P. Safran, Benedito A. Carneiro
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P021.
https://doi.org/10.1158/1535-7163.TARG-21-P021
Published: 01 December 2021
View article titled, Abstract P021: Genomic biomarkers for response to 9-ING-41, a small molecule selective glycogen synthase kinase-3 (GSK-3) inhibitor, in pancreas cancer: Preliminary results
Journal Articles

The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer

Brittany A. Borden, Yasmine Baca, Joanne Xiu, Fabio Tavora, Ira Winer, Benjamin A. Weinberg, Ari M. Vanderwalde, Sourat Darabi, W. Michael Korn, Andrew P. Mazar, Francis J. Giles, Lorin Crawford, Howard Safran, Wafik S. El-Deiry, Benedito A. Carneiro
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (1): 183–190.
https://doi.org/10.1158/1535-7163.MCT-20-0497
Published: 05 January 2021
View article titled, The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer
Open the PDF for The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B092: Assessment of glycogen synthase kinase-3 beta (GSK3β) genomic landscape to inform use of cancer therapeutics

Brittany A. Borden, Lorin Crawford, Howard P. Safran, Francis J. Giles, Wafik S. El-Deiry, Benedito A. Carneiro
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): B092.
https://doi.org/10.1158/1535-7163.TARG-19-B092
Published: 01 December 2019
View article titled, Abstract B092: Assessment of glycogen synthase kinase-3 beta (GSK3β) genomic landscape to inform use of cancer therapeutics
Journal Articles

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support

Young Kwang Chae, Alan P. Pan, Andrew A. Davis, Sandip P. Patel, Benedito A. Carneiro, Razelle Kurzrock, Francis J. Giles
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (12): 2645–2655.
https://doi.org/10.1158/1535-7163.MCT-17-0597
Published: 03 December 2017
View article titled, Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support
Open the PDF for Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining “Actionability” of a Molecular Lesion and Patient Management Support in another window
Journal Articles

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer

Young Kwang Chae, Andrew A. Davis, Sarika Jain, Cesar Santa-Maria, Lisa Flaum, Nike Beaubier, Leonidas C. Platanias, William Gradishar, Francis J. Giles, Massimo Cristofanilli
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (7): 1412–1420.
https://doi.org/10.1158/1535-7163.MCT-17-0061
Published: 04 July 2017
View article titled, Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer
Open the PDF for Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification

Yasuyuki Yoshida, Tomoko Ozawa, Tsun-Wen Yao, Wang Shen, Dennis Brown, Andrew T. Parsa, Jeffrey J. Raizer, Shi-Yuan Cheng, Alexander H. Stegh, Andrew P. Mazar, Francis J. Giles, Jann N. Sarkaria, Nicholas Butowski, Theodore Nicolaides, C. David James
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (12): 2919–2929.
https://doi.org/10.1158/1535-7163.MCT-14-0306
Published: 04 December 2014
View article titled, NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with <em>EGFR</em> Amplification
Open the PDF for NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with <em>EGFR</em> Amplification in another window
Includes: Supplementary data
Journal Articles

Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening

Richard J. Rickles, Winnie F. Tam, Thomas P. Giordano, III, Laura T. Pierce, Melissa Farwell, Douglas W. McMillin, Antoaneta Necheva, David Crowe, Mei Chen, William Avery, Vikram Kansra, Steffan T. Nawrocki, Jennifer S. Carew, Francis J. Giles, Constantine S. Mitsiades, Alexis A. Borisy, Kenneth C. Anderson, Margaret S. Lee
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (7): 1432–1442.
https://doi.org/10.1158/1535-7163.MCT-11-0925
Published: 05 July 2012
View article titled, Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening
Open the PDF for Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening in another window
Includes: Supplementary data
Journal Articles

Abstract B272: The novel PIM kinase inhibitor SGI‐1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma

Devalingam Mahalingam, Ernest Medina, Ronan T. Swords, Kevin R. Kelly, David Bearss, Gavin Choy, Pietro Taverna, Jennifer S. Carew, Francis J. Giles, Steffan T. Nawrocki
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B272.
https://doi.org/10.1158/1535-7163.TARG-09-B272
Published: 10 December 2009
View article titled, Abstract B272: The novel PIM kinase inhibitor SGI‐1776 significantly enhances the preclinical activity of sunitinib in renal cell carcinoma